SBSteven M. Bray

Steven M. Bray

*This is an algorithmically generated author record based on publicly available information.

Steven M. Bray has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs

    by Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, et al.

    Background: Patients with cancer are at increased risk of QT interval prolongation because of polypharmacy and concomitant use of QT‐prolonging medications. Drug–drug interactions (DDIs) may further increase this risk. Outpatient electrocardiogram (ECG) monitoring appears to be underused among patients receiving oral anticancer drugs (OADs). Our study objective was to evaluate the prevalence and characteristics of potential QT interval–prolonging drug–drug interactions (QT pDDIs) in patients with cancer receiving OAD therapy. Methods: A retrospective observational study was conducted using electronic health record data from 3697 patients with advanced cancer. Patients who received at least one OAD were included in the analysis. Potential QT‐related DDIs were identified through overlap prescriptions of concomitant medications associated with QT prolongation and/or Cytochrome P450‐ (CYP‐) or drug transporter‐mediated interactions during OAD exposure. Descriptive analyses were performed to characterize the prevalence and types of QT pDDIs. Results: Of the 3697 patients, 1732 (46.8%) received at least one OAD and were included in the analysis. Of these, 17.1% experienced at least one QT pDDI. Among those patients, 47.5% experienced PD‐QT pDDIs only, 21.2% experienced PK‐QT pDDIs only, and 31.3% experienced both PD‐ and PK‐QT pDDIs during OAD exposure. Concurrent PD and PK mechanisms occurred simultaneously in 30.6% of patients with QT‐pDDIs. Approximately 48% of identified QT pDDIs involved at least one OAD, most commonly pazopanib (13.5%), palbociclib (11.3%), and vandetanib (8.4%). Conclusion: QT pDDIs were common among patients with cancer receiving OADs, highlighting the importance of comprehensive DDI screening, careful medication review, and enhanced cardiac monitoring strategies in oncology practice.

  • Open Access

    Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection

    by Parvathi Sudha, Phillip Pham, Wen Niu, Enze Liu, Lin Wang, Gillian Truong, Cameron Ligocki, Ramzi Al-Azzawi, Malini Surapenini, Steven M. Bray, et al.

    Here, we present the case for next-generation sequencing of samples from patients with multiple myeloma (MM), not only identify high-risk markers but also mutations and deletions relating to immunomodulatory drugs (IMiD), and more importantly to guide the sequencing of immunotherapy regimens in response to intrinsic antigen escape as a means of treatment resistance and relapse. This is a single-center study of CD138+ selected (n = 134) bone marrow aspirate samples from patients with smoldering MM (n = 11) and MM (newly diagnosed, n = 38; relapsed, n = 79). Samples were sequenced using a targeted panel in a clinical diagnostics laboratory. Data were analyzed for high-risk markers, treatment-related resistance mechanisms, and precision medicine targets to guide the future treatment of patients in the clinic. High-risk markers, including t(4;14), t(14;16), t(14;20), gain or amplification 1q, deletion of CDKN2C, and deletion or mutation of TP53, were identified in 15% samples from patients with newly diagnosed. At relapse, alterations in the cereblon degradation pathway were found in 24.3% of IMiD-treated patients. Deletions of 4p (CD38) were also enriched in patients who received anti-CD38 treatment (P = .03), which were mostly monoallelic. Deletions and mutations were detected in TNFRSF17-encoding B-cell maturation antigen (BCMA) in patients treated with anti-BCMA regimens, and the information was used to change the treatment of the patients. Targeted sequencing of diagnostic samples of patients with MM can be used for risk stratification and to monitor and adjust treatments as resistance mechanisms evolve.


  • Fidelity of Next-Generation Sequencing to Predict Human Epidermal Growth Factor 2 Overexpression Across Solid Tumors

    by Mya Tran, Christopher A. Fausel, Steven Bray, Guanglong Jiang, Erica Cantor, Santosh Philips, Fei Shen, Bryan P. Schneider

    PURPOSE: Human epidermal growth factor 2 (HER2/ERBB2) has recently become a pan-tumor–agnostic target after the approval of trastuzumab deruxtecan for solid tumors with HER2 overexpression (3+). HER2 positivity is currently assessed by immunohistochemistry (IHC) and/or HER2 amplification through in situ hybridization (ISH), owing to the fact that HER2 overexpression is secondary to HER2 gene amplification in many cases. Outside of breast/gastroesophageal cancer, the optimal IHC scoring method to assess overexpression across solid tumors remains undefined. Next-generation sequencing (NGS) is frequently used in practice and could be leveraged to predict HER2 positivity. However, less is known regarding the correlation between these methodologies. We sought to evaluate the ability of NGS to predict HER2 overexpression. METHODS: We compared the concordance of HER2 IHC and/or ISH results with HER2 amplification status detected by NGS in 1,009 patients with solid tumors who were referred to the Indiana University Precision Genomics program between September 2021 and October 2024. RESULTS: HER2 3+ by IHC was identified in 4.3% (43 of 1,009) of cases. When including HER2 2+/ISH-positive (ISH+), the overall incidence of HER2 positivity was 5.1% (51 of 1,009). HER2 amplification was not detected by NGS in 20.9% (9 of 43) of HER2 3+ and 75.0% (6 of 8) of HER2 2+/ISH+ cases. The rate of discordance varies across the type of NGS testing platform and sample status, with the highest incidence seen in liquid NGS (80.3%) and the lowest incidence observed when the same sample was used for testing (26.7%). CONCLUSION: Relying solely on NGS-based HER2 amplification could result in missing cases of HER2 positivity and thus deprive patients of anti-HER2 therapy options. NGS, IHC, and/or ISH should be used as complementary tools for optimal detection of HER2 positivity.

  • Open Access

    Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

    by Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, et al.

    Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

  • Open Access

    Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

    by Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, et al.

    Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

  • Open Access

    Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

    by Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, et al.

    Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

  • Open Access

    Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

    by Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, et al.

    Purpose:The PI3K pathway is dysregulated in the majority of triple-negative breast cancers (TNBC), yet single-agent inhibition of PI3K has been ineffective in TNBC. PI3K inhibition leads to an immediate compensatory upregulation of the Wnt pathway. Dual targeting of both pathways is highly synergistic against TNBC models in vitro and in vivo. We initiated a phase I clinical trial combining gedatolisib, a pan-class I isoform PI3K/mTOR inhibitor, and cofetuzumab pelidotin, an antibody–drug conjugate against the cell-surface PTK7 protein (Wnt pathway coreceptor) with an auristatin payload.Patients and Methods:Participants (pt) had metastatic TNBC or estrogen receptor (ER) low (ER and PgR < 5%, HER2-negative) breast cancer, and had received at least one prior chemotherapy for advanced disease. The primary objective was safety. Secondary endpoints included overall response rate (ORR), clinical benefit at 18 weeks (CB18), progression-free survival (PFS), and correlative analyses.Results:A total of 18 pts were enrolled in three dose cohorts: gedatolisib 110 mg weekly + cofetuzumab pelidotin 1.4 mg/kg every 3 weeks (n = 4), 180 mg + 1.4 mg/kg (n = 3), and 180 mg + 2.8 mg/kg (n = 11). Nausea, anorexia, fatigue, and mucositis were common but rarely reached ≥grade 3 severity. Myelosuppression was uncommon. ORR was 16.7% (3/18). An additional 3 pts had stable disease (of these 2 had stable disease for >18 weeks); CB18 was 27.8%. Median PFS was 2.0 months (95% confidence interval for PFS: 1.2–6.2). Pts with clinical benefit were enriched with genomic alterations in the PI3K and PTK7 pathways.Conclusions:The combination of gedatolisib + cofetuzumab pelidotin was well tolerated and demonstrated promising clinical activity. Further investigation of this drug combination in metastatic TNBC is warranted.

  • Open Access

    Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

    by Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, et al.

    Purpose:The PI3K pathway is dysregulated in the majority of triple-negative breast cancers (TNBC), yet single-agent inhibition of PI3K has been ineffective in TNBC. PI3K inhibition leads to an immediate compensatory upregulation of the Wnt pathway. Dual targeting of both pathways is highly synergistic against TNBC models in vitro and in vivo. We initiated a phase I clinical trial combining gedatolisib, a pan-class I isoform PI3K/mTOR inhibitor, and cofetuzumab pelidotin, an antibody–drug conjugate against the cell-surface PTK7 protein (Wnt pathway coreceptor) with an auristatin payload.Patients and Methods:Participants (pt) had metastatic TNBC or estrogen receptor (ER) low (ER and PgR < 5%, HER2-negative) breast cancer, and had received at least one prior chemotherapy for advanced disease. The primary objective was safety. Secondary endpoints included overall response rate (ORR), clinical benefit at 18 weeks (CB18), progression-free survival (PFS), and correlative analyses.Results:A total of 18 pts were enrolled in three dose cohorts: gedatolisib 110 mg weekly + cofetuzumab pelidotin 1.4 mg/kg every 3 weeks (n = 4), 180 mg + 1.4 mg/kg (n = 3), and 180 mg + 2.8 mg/kg (n = 11). Nausea, anorexia, fatigue, and mucositis were common but rarely reached ≥grade 3 severity. Myelosuppression was uncommon. ORR was 16.7% (3/18). An additional 3 pts had stable disease (of these 2 had stable disease for >18 weeks); CB18 was 27.8%. Median PFS was 2.0 months (95% confidence interval for PFS: 1.2–6.2). Pts with clinical benefit were enriched with genomic alterations in the PI3K and PTK7 pathways.Conclusions:The combination of gedatolisib + cofetuzumab pelidotin was well tolerated and demonstrated promising clinical activity. Further investigation of this drug combination in metastatic TNBC is warranted.

  • Open Access

    Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

    by Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, et al.

    Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

  • Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

    by Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, et al.

    Purpose: The PI3K pathway is dysregulated in the majority of triple-negative breast cancers (TNBC), yet single-agent inhibition of PI3K has been ineffective in TNBC. PI3K inhibition leads to an immediate compensatory upregulation of the Wnt pathway. Dual targeting of both pathways is highly synergistic against TNBC models in vitro and in vivo. We initiated a phase I clinical trial combining gedatolisib, a pan-class I isoform PI3K/mTOR inhibitor, and cofetuzumab pelidotin, an antibody–drug conjugate against the cell-surface PTK7 protein (Wnt pathway coreceptor) with an auristatin payload. Patients and Methods: Participants (pt) had metastatic TNBC or estrogen receptor (ER) low (ER and PgR < 5%, HER2-negative) breast cancer, and had received at least one prior chemotherapy for advanced disease. The primary objective was safety. Secondary endpoints included overall response rate (ORR), clinical benefit at 18 weeks (CB18), progression-free survival (PFS), and correlative analyses. Results: A total of 18 pts were enrolled in three dose cohorts: gedatolisib 110 mg weekly + cofetuzumab pelidotin 1.4 mg/kg every 3 weeks (n = 4), 180 mg + 1.4 mg/kg (n = 3), and 180 mg + 2.8 mg/kg (n = 11). Nausea, anorexia, fatigue, and mucositis were common but rarely reached ≥grade 3 severity. Myelosuppression was uncommon. ORR was 16.7% (3/18). An additional 3 pts had stable disease (of these 2 had stable disease for >18 weeks); CB18 was 27.8%. Median PFS was 2.0 months (95% confidence interval for PFS: 1.2–6.2). Pts with clinical benefit were enriched with genomic alterations in the PI3K and PTK7 pathways. Conclusions: The combination of gedatolisib + cofetuzumab pelidotin was well tolerated and demonstrated promising clinical activity. Further investigation of this drug combination in metastatic TNBC is warranted.